G. W. Kasule

Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda

M. Joloba, Samuel Kyobe, D. Kateete, 2018, PloS one.

Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families

M. Joloba, D. Kateete, G. W. Kasule, 2016, BMC Infectious Diseases.

The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda

F. Cobelens, M. Joloba, D. Kateete, 2014, BMC Infectious Diseases.

Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis

F. Cobelens, M. Joloba, W. Ssengooba, 2015, BMC Public Health.

Implementation of GeneXpert MTB/Rif proficiency testing program: A Case of the Uganda national tuberculosis reference laboratory/supranational reference laboratory

M. Joloba, E. Kigozi, G. W. Kasule, 2021, PloS one.

Phylogenetic lineages of tuberculosis isolates and their association with patient demographics in Tanzania

N. Range, M. Hoelscher, M. Joloba, 2022, BMC Genomics.

First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda

Isam Adam, M. Joloba, G. Mboowa, 2021, Antimicrobial resistance and infection control.

Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis Patients in Uganda: Results of the First National Survey

M. Joloba, A. Date, F. Adatu, 2013, PloS one.

The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis

Daniel J. Wilson, Youwen Qin, M. Inouye, 2022, The Lancet. Microbe.

Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda

F. Cobelens, B. D. de Jong, C. Meehan, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

M. Joloba, D. Kateete, P. Arube, 2019, BMC Pulmonary Medicine.